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http://www.epigeneticsandchromatin.com/content/7/1/21RESEARCH Open AccessDNA methylation dynamics during ex vivo
differentiation and maturation of human
dendritic cells
Xue Zhang1†, Ashley Ulm2†, Hari K Somineni2†, Sunghee Oh3, Matthew T Weirauch4, Hong-Xuan Zhang5,
Xiaoting Chen6, Maria A Lehn7, Edith M Janssen7 and Hong Ji2*Abstract
Background: Dendritic cells (DCs) are important mediators of innate and adaptive immune responses, but the
gene networks governing their lineage differentiation and maturation are poorly understood. To gain insight into
the mechanisms that promote human DC differentiation and contribute to the acquisition of their functional
phenotypes, we performed genome-wide base-resolution mapping of 5-methylcytosine in purified monocytes and
in monocyte-derived immature and mature DCs.
Results: DC development and maturation were associated with a great loss of DNA methylation across many
regions, most of which occurs at predicted enhancers and binding sites for known transcription factors affiliated
with DC lineage specification and response to immune stimuli. In addition, we discovered novel genes that may
contribute to DC differentiation and maturation. Interestingly, many genes close to demethylated CG sites were
upregulated in expression. We observed dynamic changes in the expression of TET2, DNMT1, DNMT3A and DNMT3B
coupled with temporal locus-specific demethylation, providing possible mechanisms accounting for the dramatic
loss in DNA methylation.
Conclusions: Our study is the first to map DNA methylation changes during human DC differentiation and maturation
in purified cell populations and will greatly enhance the understanding of DC development and maturation and aid in
the development of more efficacious DC-based therapeutic strategies.
Keywords: DNA methylation, Human dendritic cells, Monocytes, Differentiation, Maturation, TET, DNMTBackground
Dendritic cells (DCs) are a heterogeneous group of bone
marrow-derived cells within various organs, which display
different cell surface phenotypes and serve different func-
tions depending on location, development, and activation
status. DCs bridge two arms of the immune response: the
innate immune response via the recognition of pathogens
through pattern-recognition receptors and the adaptive
immune response via the activation of T and B cells [1].
They can exist in two developmental states, immature
(iDC) and mature (mDC), with alternate functional charac-
teristics in each state. The induction of DC differentiation* Correspondence: Hong.Ji@cchmc.org
†Equal contributors
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Dedication waiver (http://creativecommons.or
unless otherwise stated.ex vivo from human and mouse peripheral monocytes
by granulocyte-macrophage colony stimulating factor
(GM-CSF) and Interleukin 4 (IL4) suggest that monocytes
may serve as an important reservoir for DC development
[2]. Mouse studies also support that monocytes can develop
in vivo into a DC-like population [3]. Like conventional
DCs (cDCs), GM-CSF and IL-4 derived DCs (iDCs)
upregulate their expression of CD11c and major histo-
compatibility complex (MHC) class II complexes and
efficiently stimulate naive T cells [4]. A widely accepted
cytokine mix can further transform iDCs into mDCs
[5]. With the FDA approval of the antigen-presenting
cell vaccine sipuleucel-T for prostate cancer, DC-based
therapeutic vaccines have become an established approach
for the treatment of established cancer. In human blood,
two major phenotypically and functionally distinct DCLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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myeloid DCs and the CD11c− CD123+ plasmatoid DCs.
The myeloid DCs have been further defined into three
subsets based on the expression of CD16, BDCA-1 and
BDCA-3 [6]. Recently, it has been demonstrated that
human BDCA3+ DCs possess characteristics of mouse
CD8α+ DCs and can induce cytotoxic T lymphocyte re-
sponses [7,8], and therefore, are the most relevant targets
for vaccination against cancer. Due to the complexity of
the lineage and difficulty in lineage determination based
on surface markers, the molecular mechanisms regulating
the development of DCs are not well understood com-
pared to other lineages such as T cells [9]. Studying the
ex vivo differentiation of monocytes into DCs may help us
better understand the differentiation of different DC sub-
types in vivo and allow for the successful generation of
more efficacious DC vaccines in the future.
As an epigenetic mechanism that regulates gene expres-
sion both in cis and in trans, DNA methylation has been
shown to regulate gene expression of related pathways
and cellular identity in the immune system [10-13]. In
mammalian cells, DNA methylation is maintained by
DNA methyl-transferases DNMT1, DNMT3A and 3B.
DNMT1 methylates hemi-methylated parent-daughter
duplexes during DNA replication, while de novo methy-
lation is predominantly carried out by DNMT3A and
3B. Several promising, yet controversial, mechanisms
have been proposed for DNA demethylation, such as
the deamination of 5mC to T, coupled with G/T mismatch
repair by DNA glycosylases [14], or the hydroxylation of
TET proteins through the generation of 5-hydroxymethyl-
cytosine (5hmC) and 5-formylcytosine (5fC) [15-17]. The
combination of methylation by DNMTs and demethylation
by TETs may contribute to the observed dynamic DNA
methylation changes during cellular differentiation [10].
DNA methylation is a potential mechanism governing
the differentiation and activation of DCs. Indeed, locus
and region-specific DNA methylation changes have been
observed during the ex vivo differentiation of monocytes
to iDCs [12,18]. A detailed study of DNA methylation
dynamics during these processes will greatly help to bet-
ter tease apart the molecular events that occur during
the transition from monocytes to iDCs, and from iDCs
to mDCs.
In this study, we established genomic maps of DNA
methylation at single nucleotide-resolution for human
monocytes and monocyte-derived immature and mature
DCs [19]. Besides identification of genes and pathways
known to be involved in DC differentiation and matur-
ation, we observed dynamic DNA methylation changes
at many novel genes, most of which are demethylated.
Interestingly, these changes occur close to the binding
sites of transcription factors that are implicated in DC
differentiation and function. In addition, we correlatedDNA methylation levels at differentially methylated
sites/points (DMPs) with expression levels of genes located
within 1,500 bp distance using published gene expression
arrays and found a general inverse correlation between
DNA methylation and gene expression levels. Time course
experiments showed that the demethylation event is
locus-specific, and is coupled with dynamic changes in
the DNA methylation machinery, including TET2, DNMT1,
DNMT3A and DNMT3B. Besides providing detailed
DNA methylome reference maps for purified mono-
cytes, iDCs and mDCs, our study demonstrated the
dynamic epigenetic regulation of genes and pathways
important for DC development and maturation, which
are potential targets to improve DC-based therapeutic
strategies.
Results
Genome-wide scanning identifies DNA methylation changes
during dendritic cell differentiation and maturation
We ex vivo differentiated monocytes (from four blood
donors) into iDCs and matured them using the Jonuleit
cytokine cocktail mix (IL-1β, IL-1α, IL-6, TNF-α and
PGE2) following the established FDA approved protocol
[see Additional file 1A] [5]. The iDCs (HLA-DRlow) and
mDCs (CD83+, CD86+ and HLA-DRhigh) were fluores-
cence-activated cell sorting (FACS) purified (>95% purity)
and subjected to further analysis [see Additional file 1B].
Using a cutoff of P value ≤0.05 and absolute differ-
ence ≥0.1, we identified 1,608 DMPs from monocytes
to iDCs and 156 DMPs from iDC to mDCs (Table 1,
Figure 1A and B). Only 6% of the identified DMPs
are located within CpG islands even though 31% of
CG sites assayed are within CpG islands. Consistent
with previous observations, our findings support that
the DNA methylation level of CGs at shores and
shelves (defined as regions that are 0 to 2 kb and 2
to 4 kb away from CpG islands, respectively) may be
more dynamic and critical during cellular differentiation
than that of CpG islands [10]. Interestingly, the vast ma-
jority of these sites are demethylated (1,367 out of 1,608
DMPs from monocytes to iDC and 139 out of 156 DMPs
from iDC to mDC) (Figure 1 and Table 1). We further
measured whole-genome DNA methylation levels using
an ELISA-based method, and confirmed the occurrence of
CG demethylation during iDC differentiation from mono-
cytes (Figure 1C). A total of 933 genes are linked to the
1,608 DMPs with DNA methylation changes from mono-
cytes to iDCs (Table 1). Among these genes, 795 genes are
exclusively linked to demethylated DMPs, 117 genes are
linked to more methylated DMPs, and 21 genes (2%) are
linked to DMPs with methylation changes in both direc-
tions [see Additional file 2A, B and C]. A total of 116
genes are linked to the 156 DMPs from iDC to mDCs,
among which 102 genes are linked to DMPs, all with
Table 1 Numbers of differentially methylated CG sites (DMPs) identified during ex vivo dendritic differentiation and
maturation
Comparisons (G1 versus G2) Numbers
of DMPsa
Locations of DMPs
relative to CpG islands (%)
Enhancer
associatede
Promoter
associatedf
Gene
associatedg
G1 > G2 G1 < G2 Islands Shoresb Shelfc >4 kbd
CD14+ versus immature dendritic cell (iDC) 1368 240 5.9 23.5 16.1 54.5 701 139 933
iDC versus mature dendritic cell (mDC) 139 17 3.3 18.2 14.9 63.6 80 9 116
aP value cutoff of 0.05, difference change of 10% in DNA methylation was used to calculate the number of DMPs (see Methods).
bShores were defined for this table as 2 kb from an island (N and S island).
cShelves were defined for this table as 2 kb-4 kb away from an island (N and S shore).
dRegions over 4 kb from an island.
e, f, gBased on HumanMethylation450 v1.2 Manifest File (http://support.illumina.com/downloads/infinium_humanmethylation450_product_files.html).
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to DMPs, all with increased methylation [see Additional
file 2D and E].
A great number of the identified demethylated CG
sites are located at enhancers (Table 1, 43.6% CG sites
from monocyte to iDCs and 51.6% from iDC to mDC).
Previous studies have shown that chromatin markers
including H3K4me1, H3K4me3 and H3K27Ac are
enriched at human enhancers [20,21] and are highly
cell-type specific. We examined the overlap between
H3K4me1, H3K4me3 and H3K27Ac markers in mono-
cytes [22] with CG sites that undergo DNA methyla-
tion changes from monocyte to iDCs, and found that
67.6% of the CG sites have H3K4me1 markers (45.5%
CG sites from iDC to mDC). More than half of these
CG sites with H3K4me1 also have H3K4me3 and
H3K27Ac markers.
We then searched for transcription factor binding
sites in 51 bp windows centered on these DMPs and
identified several transcription factors with known
roles in dendritic cell lineage specification (Figure 1D,
Additional file 3, see Methods). The consensus sequence
of the most strongly enriched motif for the monocyte to
iDC transition is TGACTGA, the AP-1 response element
bound by bZIP transcription factors JUN, FOS, BATF,
BATF3, as well as IRF4, and IRF8 [23]. Among these,
IRF8 is a transcription factor that distinguishes a DC-
committed progenitor from myeloid progenitors [24]
and is important for the development of several DC
subsets [25,26]. In addition, BATF3 binds to JUN and
is required for the normal development of CD8α+ cDCs
in mouse models and BDCA3+ DCs in humans [27-29].
Furthermore, IRF4 interacts with PU.1 and is required
for the development of CD11b+ cDCs [30]. Motifs most
strongly enriched for the iDC to mDC transition con-
tain a GGAA core, which binds to transcription factors
including BCL11A, SPIB and RELA. Indeed, BCLLA
and SPIB may regulate pDC development [31,32], while
RELA is a NF-κB family member that regulates CD11c+
DC generation [33] and cytokine production in myeloid
DCs [34].Pathway analysis reveals significant genes and networks
during dendritic cell differentiation
We next performed pathway analysis to identify biological
processes that undergo DNA methylation changes during
DC differentiation and maturation, stratified by directions
of change [see Additional files 4 and 5]. First, components
of the IL-4 and GM-CSF signaling pathways were
demethylated, consistent with our approaches and sug-
gesting that these molecules induce DC differentiation
from monocytes through the modification of DNA
methylation. The genes involved in cytokine produc-
tion and interaction with T cells, such as IL-6, IL-10,
IL-12 and T cell receptor signaling were demethylated
when exposed to differentiation stimuli [see Additional
file 4A], indicating an epigenetic priming of iDCs by
IL-4 and GM-CSF for their secretion of cytokines and
activation of naïve T cells.. Consistently, upstream regula-
tor analysis in Ingenuity Pathway Analysis (IPA) revealed
that targets of IL-1α, IL-1β, IL-6 and TNF-α are differen-
tially methylated in iDCs by IL-4 and GM-CSF induction
[see Additional file 6]. These cytokines are included in the
DC maturation cocktail, supporting a priming process for
the response of the immature DCs to cytokine stimuli.
Second, an IPA search on demethylated genes from
monocytes to iDCs [see Additional file 2A] resulted in a
number of enriched pathways including Aryl Hydrocarbon
Receptor signaling (AhR), PPAR signaling, AKT signaling,
Integrin signaling, IL-6 signaling, IL-10 signaling, IL-12
signaling and production, T cell receptor signaling, NRF2-
mediated oxidative stress response, granulocyte adhesion
and diapedesis, caveolae-mediated endocytosis signaling,
clathrin-mediated endocytosis signaling, and macropino-
cytosis signaling (Figure 2A and Additional file 4A). Inter-
estingly, many of these demethylated pathways are
required for DCs to recognize and process antigens and
present them to T cells, which is in line with the func-
tional characteristics of iDCs (Figure 2A). For example,
SRC (Rous sarcoma oncogene) encodes a tyrosine-protein
kinase that participates in many immune pathways.
Proteins encoded by SRC, AHRR (aryl-hydrocarbon recep-
tor repressor), and CYP1B1 (cytochrome P450, family 1,
A C
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Figure 1 DNA methylation changes occur at non-CGI and transcription factor binding sites during dendritic cell (DC) differentiation
and maturation. A) Heatmap showing the CG sites with greater than 10% methylation difference between monocytes and immature dendritic
cells (iDCs) among all samples. B) Heatmap showing the CG sites with greater than 10% methylation difference between iDCs and mature dendritic
cells (mDCs) among all samples. C) Global DNA methylation levels measured by 5mC ELISA in monocytes, sorted iDCs and sorted mDCs used for
microarray analysis. Four technical replicates were used in each cell type, and results are shown as mean ± SD. *P <0.05, **P <0.01, n.s., nonsignificant,
paired t test. D) Examples of potential transcription factor binding sites within 50 bp around demethylated CG sites.
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http://www.epigeneticsandchromatin.com/content/7/1/21subfamily B, polypeptide 1) participate in the AhR sig-
naling cascade, which mediates the response of DCs to
dioxin [35-37], and is involved in the regulation of nor-
mal immune cell development and the immuneresponse of DCs following lipopolysaccharide challenge
or influenza virus infection [38,39]. PPARG (peroxisome
proliferator-activated receptor gamma) encodes a lipid-
activated transcription factor that positively regulates
A PPARG
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Figure 2 Locus-specific bisulfite sequencing validates microarray findings. DNA methylation changes in SRC, AHRR, CYP1B1, PPARG, AKT1,
HMOX1, ITGB2, and DNMT3B (A), and PLEKHG6, PDE4B, IL23R, CD86, IL10, CCR7 and CD59 (B). Four technical replicates of flow-purified cells were
used in each cell type, and results are shown as mean ± SD.
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http://www.epigeneticsandchromatin.com/content/7/1/21myeloid DC maturation and functions [40-43]. However,
the detailed roles of each of the genes in DC differenti-
ation and maturation are unclear. We also observed an
80% decrease in DNA methylation at a CG site located
within the second intron of AKT1 (v-akt murine thymoma
viral oncogene homolog 1). AKT plays a critical role in
proinflammatory-mediated DC survival and maturation;
human monocyte-derived DCs with constitutively active
lipid raft-targeted AKT1 survived significantly longer and
had promoted antigen-specific T-cell responses, while
downregulation of AKT1 reduced their life span [44]. In
addition, the methylation level at a CG site located at the
3′ UTR of HMOX1 (heme oxygenase 1) was found to be
reduced. The heme oxygenase 1 (HO-1) encoded by this
gene is a stress responsive gene whose expression is
induced by a variety of stimuli including heme, heavy
metals, inflammatory cytokines, and nitric oxide (reviewed
in [45]). Induction of HO-1 inhibits lipopolysaccharide
(LPS)-induced dendritic cell phenotypic maturation and
the secretion of proinflammatory cytokines, resulting in
the inhibition of alloreactive T-cell proliferation [46,47].
The activation of these genes is consistent with the role of
iDC in taking up antigens by phagocytosis or macropino-
cytosis and processing the internalized antigen.
Pathway analysis reveals significant genes and networks
during dendritic cell maturation
From iDC to mDC, the pathways involved in communi-
cation between innate and adaptive immune cells, the
complement system, and cross talk between DCs and nat-
ural killer cells were demethylated [see Additional file 5A].
This is consistent with the function of mDC in antigen
presentation to effector cells through the expression of
MHC and membrane-associated co-stimulatory molecules,
and secretion of co-stimulatory cytokines. Specifically, we
found that CG sites located in myosin-interacting guanine
nucleotide exchange factor (PLEKHG6), phosphodiesterase
4B (PDE4B), interleukin 23 receptor (IL23R), CD86, inter-
leukin 10 (IL10) and chemokine receptor 7 (CCR7), and
CD59 were significantly demethylated from iDC to mDC
(Figure 2B). Among these genes, the expression of PDE4B
is low in iDCs and is upregulated in mDCs (GSE7509) [48],
which is consistent with its high methylation in iDCs and
reduced DNA methylation level in mDCs. Addition of
PDE4 inhibitor during DC maturation impairs IL12 and
TNF-α production in response to LPS and CD40 ligand
and destroys the capacity to generate Th1 cells [49]. IL23R
encodes interleukin-23 receptor, which pairs with IL12RB1
to form the receptor for IL-23A/IL-23. This receptor is
expressed in T cells, and IL-23A signaling is required for
the survival and/or expansion of Th17 cells [50]. Although
this protein is also expressed on monocyte-derived DCs
(GSE6965) [51], the role of IL23R in DC maturation and
function is unknown. Further, CD86 is a surface markerfor DCs, and binding of this protein to CD28 acts as a
co-stimulatory signal for T cell activation by DCs [52,53].
The methylation at a CG site located in the IL10 promoter
is reduced in mDCs compared to iDCs. IL10 may regulate
DC differentiation and maturation because addition of
IL10 to the differentiation cocktail generates mDCs with
distinct phenotypes [54] and these DCs have an impaired
capacity to induce a Th1-type response in vivo, leading
to the development of Th2 lymphocytes [55]. CCR7 is a
chemokine receptor necessary to direct dendritic cells
(DCs) to secondary lymphoid nodes and to elicit an
adaptive immune response [56-58]. Similarly, as a cell
surface glycoprotein that regulates complement-mediated
cell lysis, CD59 is constitutively expressed in monocyte
derived-DCs. However, how this protein regulates DC func-
tion is not clear. Maturation by LPS or TNF-α/IL-1/PGE2
significantly increases CD59 expression [59], probably
through demethylation of the promoter of CD59 as sug-
gested by our study.
DNA methylation changes are correlated with gene
expression profiles
DNA methylation provides a mechanism for robust and
epigenetically heritable gene silencing. DNA methylation
at CpG islands has been the focus of many studies and
is generally associated with gene silencing. However,
significant methylation changes do not occur exclusively
at CpG islands. CpG island shores and shelves are also
closely associated with transcriptional silencing [10,60,61].
To further understand the role of observed DNA methyla-
tion changes, we correlated our DNA methylation data
with publically available gene expression data (Affymetrix
Human genome U133 Plus 2) for monocytes, iDCs and
mDCs (GEO: GSE7509) [48,62]. In general, we found a
significant negative correlation between DNA methylation
and gene expression at differentially methylated loci from
monocytes to iDCs at CpG shores, shelves and open sea
(Figure 3). This is in agreement with previous findings in
hematopoietic lineage commitment, and highlights the
significance of DNA methylation in gene silencing. Sev-
eral validated demethylated CG sites are associated with
a significant increase in gene expression (Figure 3).
From iDCs to mDCs, there is a similar relationship be-
tween DNA methylation and gene expression, although
none of them reached statistical significance likely due
to the smaller number in each category [see Additional
file 7].
Expression of DNA methylation machinery couples with
dynamic DNA methylation changes
Among the DMPs we discovered, we have observed exten-
sive demethylation during monocyte differentiation into
iDCs and from iDCs to mDCs (Table 1, Figure 1A and B).
One of the mechanisms that could account for this
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Figure 3 Correlation of DNA methylation changes with gene expression alterations during dendritic cell (DC) differentiation. CG sites
with significant DNA methylation changes were grouped by its relative distance to CGI. A. CpG island; B. CG shores: 0 to 2 kb from an island; C.
Shelves: 2 to 4 kb from an island; D. Open sea: 4 kb away from an island. The changes in expression levels of differentially expressed genes (false
discovery rate (FDR) <0.05) were then correlated with changes in beta values of differentially methylated points (DMPs), and Pearson’s correlation
coefficients were reported for CG sites in each category. CG sites validated in Figure 2 whose associated gene expression levels also significantly
altered were highlighted with different colors.
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transferases, including DNMT1, DNMT3A and DNMT3B.
Surprisingly, independent analyses of monocytes, iDCs
and mDCs generated from individual donors showed a
significant increase in the expression levels of DNMT1
and DNMT3A during the differentiation from monocyte
to iDC (day 1 to 4 versus day 0) and a significant decrease
at 24 hours after the addition of maturation cocktail (ma-
ture day-1 versus day-4) [see Additional file 8A]. However,
the later significance with DNMT3A was lost when we an-
alyzed pooled data from four individual donors, possibly
due to the variability between donors (Figure 4A). The
respective increase and decrease in the expression levels
of DNMT1 during differentiation and maturation was in
agreement with the previously published dataset (GEO:
GSE7509). However, our finding of DNMT3A during the
differentiation of monocyte to iDC contradicts the public
dataset, where they reported a significant decrease. In
addition, our time-course experiments found a novel and
significant upregulation of DNMT3B 48 hours after
the addition of the maturation cocktail (mature day-2)
(Figure 4 and Additional file 8A). Collectively, our data
suggest de novo methylation upon the initiation ofdifferentiation and demethylation upon the initiation of
maturation, followed by de novo methylation during
maturation.
Another mechanism for active demethylation is TET
protein-mediated oxidation of 5mC to 5hmC, a potential
intermediate for active DNA demethylation, followed by
secondary reactions that eventually lead to restoration of
cytosine. The expression of TET1 was very low and
there was no detectable change during the course of this
experiment. However, the expression levels of TET2
were highly upregulated as early as day 1 during mono-
cyte to iDC differentiation (Figure 4B and Additional
file 8B). The expression of TET3 remained unchanged
during the differentiation as well as maturation (Figure 4B).
It has been previously shown that region-specific demeth-
ylation by TET protein through the production of 5hmC
is promoted by PPARγ-induced PARylation in adipocytes
[63]. Indeed, we found that many components within the
PPARγ pathway, including PPARγ itself, were demethy-
lated from monocyte to iDC (Figure 2A), suggesting that
this pathway might also be involved in DC differentiation.
To further examine the temporal dynamics of DNA
methylation changes, we used an ELISA-based methodology
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Figure 4 Dynamic changes in expression levels of TET2/3 and DNMTs. Gene expression levels of DNMT1, DNMT3A, and DNMT3B (A), TET2, TET3 in
(B). Independent experiments for each donor were performed and expression levels were normalized to GADPH, and three biological replicates were
used in each condition. Bar graphs shown in this figure represent pooled data analyses from all the four independent experiments. Comparisons were
made for Day-0 versus Day-1, Day-4 versus Mature Day-1, and Mature Day-1 versus Mature Day-2 using paired t-test. *P <0.05, **P <0.01.
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during the course of monocyte differentiation and iDC
maturation. We observed a trend of loss in gross levels of
5mC during the course of differentiation [see Additional
file 9A, day-0 to day-4], consistent with what we have
observed in purified cell populations. However, after the
addition of maturation cocktail, there was a significant re-
duction in global 5mC (P = 0.044, mature day-1 versus
day-4), followed by a trend of increase. This coincides with
the upregulation of TETs and DNMTs, suggesting that
TETs and DNMTs may be responsible for the dynamic
changes in DNA methylation. However, the level of 5hmC
was not significantly altered during DC differentiation
although there was a trend of loss during maturation [see
Additional file 9B, P = 0.052]. Parallel analysis of purified
monocytes, iDCs and mDCs with this same approach also
showed no significant changes in global 5hmC level [see
Additional file 9C].
Gene-specific demethylation dynamics regulate expression
profiles
In order to better characterize the gene- and locus-specific
early and late methylation modifications, we measured themethylation level at specific CG sites in SRC, PLEKHG6
and ITGB2, which showed a huge erasure of DNA methyla-
tion (approximately 70% to 80%) either from monocytes to
iDCs or from iDCs to mDCs during this time course. The
two CG sites in SRC were demethylated as early as 24 hours
after the addition of IL-4 and GM-CSF and stayed the same
for rest of the experiment, suggesting that demethylation
of this gene is an early active event in DC differentiation
(Figure 5A). This demethylation was associated with
significant upregulation of SRC expression at 24 hours
(Figure 5B), consistent with previous reports (GSE7509,
Figure 3B). This change in DNA methylation couples with
an increase in the expression of DNMT1, DNMT3A, and
TET2 (Figure 4). In contrast, the CG site located at the 5′
UTR of PLEKHG6 was gradually demethylated with IL-4
and GM-CSF treatment, and was completely demethylated
after the addition of the maturation cocktail, suggesting that
the erasure was more of a passive, steady process occurring
over a period of time. It is likely that the demethylation in
PLEKHG6 does not directly regulate gene expression, be-
cause, despite the differences in DNA methylation dynam-
ics in SRC and PLEKHG6, their expression dynamics are
similar (Figure 5A and B). The expression of SRC and
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Figure 5 Locus-specific dynamic DNA methylation and expression changes during dendritic cell (DC) differentiation and maturation.
DNA methylation at CG sites at the promoter of SRC, PLEKHG6 and ITGB2 (A) and gene expression changes (B) were measured during the
differentiation of monocyte into iDC (day 0 to day 4) and immature dendritic cell (iDC) maturation into mature dendritic cell (mDC) (day 4 to
Mature day 1 to Mature day 2). iDCs without addition of maturation cocktail were grown for additional two days as well (day 5 and 6). Expression
level in B was normalized to GADPH, and three biological replicates were used in each condition. One representative experiment among four
replicates is shown here. Comparisons were made for Day 0 versus Day-1, Day-4 versus Mature Day-1, and Mature Day-1 versus Mature Day-2
using paired t-test. *P <0.05, **P <0.01, ***P <0.001, n.s., nonsignificant.
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remained almost constant for the rest of the experiment,
similar to previous reports (GEO: GSE7509) (Figure 5B).
The methylation level of two CG sites in ITGB2 (CG1 and
CG2) was reduced to a stable level in 2 days (Figure 5A).
However, the demethylation of CG1 is much slower than
CG2, and the change of CG2 is more associated with
the rapid regulation of ITGB2 at 24 hours (Figure 5B).
Consistent with the published dataset (GSE7509), theexpression of ITGB2 was significantly upregulated during
the differentiation of monocytes into iDCs, and was sig-
nificantly downregulated during their maturation. Collect-
ively, our observations demonstrated that the alteration of
DNA methylation for these CG sites does not occur at the
same time, and their impacts on gene expression may
differ. This suggests delicate, time-specific epigenetic pro-
gramming during development and possibly site-specific
mechanisms for DNA demethylation.
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In order to enhance our understanding of DNA methyla-
tion in DC lineage commitment and cellular response to
external stimuli, we established single nucleotide-resolution
genome-wide and locus-specific DNA methylation studies
for CD14+ monocytes, monocyte-derived dendritic cells
(iDCs), and DCs matured by Jonuleit cocktail (mDCs).
Dynamic DNA methylation changes, predominately an
erasure of DNA methylation, occurred during these two
ex vivo processes, particularly around enhancers and bind-
ing sites for transcription factors known for dendritic cell
lineage specification. Besides the identification of previously
studied genes and pathways involved in dendritic cell func-
tion, our analysis also revealed many novel candidate genes,
which are likely important for dendritic cell differentiation
and response to stimuli. A negative correlation between
methylation changes at CG sites and the expression of
nearby genes was found independent of the location of CG
sites, suggesting interplay between these two regulatory
mechanisms. Time-course studies of enzymes involved in
DNA methylation maintenance revealed dynamic changes
in the expression level of TET2, DNMT1, DNMT3A and
DNMT3B during differentiation and maturation, indicating
that these enzymes may account for such function-specific
and location-specific variations in DNA methylation.
Our analysis reveals novel candidates involved in
dendritic cell (DC) differentiation and maturation
Dendritic cells are antigen-presenting cells that excel at
activating naïve T-cells, and in their steady state they act
as sentinels that detect pathogens. When activated by these
pathogens, they initiate the body’s innate and adaptive im-
mune responses through the secretion of cytokines along
with the presentation of antigenic peptides on MHCs. The
functions of the known genes detected in our analyses are
consistent with the functional switch of DCs between the
steady and activated states (Figure 2). In addition, we
were able to uncover many novel candidate genes for
studying DC differentiation and activation. One candidate
is PLEKHG6, a gene that encodes a guanine nucleotide
exchange factor that can activate small GTPase RHOG
and RAC1, and form a complex with ezrin and MYH10.
Ezrin recruits PLEKHG6 to the apical pole of epithelial
cells, where PLEKHG6 induces the formation of microvilli
and membrane ruffles [64]; this interaction between
PLEKHG6 and ezrin is required for EGF-stimulated
macropinocytosis. PLEKHG6 can also form a complex
with MYH10 and RHOA, which is located at the cleavage
furrow to advance furrow ingression during cytokinesis
[65,66]. To date, no studies have addressed the role of
PLEKHG6 in dendritic cell maturation. However, our
observations of greatly reduced methylation levels at a
CG site at the 5′-UTR of PLEKHG6 as well as at CG
sites in the 5′-UTR of its interacting partner RHOG,and the second intron of MYH10 suggest that this
complex may play a role in the acquisition of functions
that are associated with a more mature DC phenotype
[67,68]. Additionally, the methylation level at a CG site
located at the 5′UTR of ITGB2 (beta 2 integrin, which
encodes integrin beta chain beta 2) was reduced by
74% (Figure 2A). The integrin beta chain beta 2 combines
with the alpha L chain to form the integrin LFA-1, and
combines with the alpha M chain to form the integrin
Mac-1. LFA-1 play a central role in leukocyte (T cells)
migration across blood vessel walls into lymph nodes and
tissues, and it is a key participant in the immunological
synapse [69,70]. However, the detailed role of LFA-1 in
dendritic cell is not clear.
TET2 and DNMTs may be responsible for the spatial and
temporal DNA methylation changes
We observed that over 1,367 CG sites underwent demeth-
ylation from monocytes to iDCs, and 139 CG sites were
demethylated during the transition from iDCs to mDCs.
Detailed locus-specific DNA methylation measurement by
pyrosequencing found that these methylation changes
were locus- and time-specific (Figure 2 and Figure 5). Re-
cently, it has been shown that TET2 is highly expressed
during monocyte differentiation and is required for active
demethylation from monocytes to iDCs [71]. However, in
this study, the expression of TET2 (normalized to HPRT)
remained nearly constant for 66 hours [71]. In contrast,
we noticed a significant increase in the expression of
TET2, as early as 24 hours after the introduction of IL-4
and GM-CSF. As the upregulation of TET2 remained
significant, even after normalizing with HPRT in our
experiments [see Additional file 8D], this disparity could
be due to the difference in the concentrations of IL-4
and GM-CSF used to generate iDCs. Further, siRNA-
mediated knockdown of TET2 in monocytes prevented
active demethylation at specific loci during monocyte
differentiation [71], which supports our observation that
TET2 expression is upregulated when demethylation
occurs. In addition, a study conducted by Kallin et al.
reported that TET2 binds to the promoter of ITGB2
during myeloid transdifferentiation and knockdown of
TET2 was associated with an incomplete activation of
ITGB2 [72], which is in line with our observation, support-
ing that TET2 may influence ITGB2 expression through
promoter demethylation. In agreement with the previous
reports, levels of TET1 were undetectable, and further-
more, and no differences were observed in TET3 expres-
sion levels, suggesting TET2 as an important player in the
erasure of DNA methylation during the differentiation of
monocyte into iDCs.
Surprisingly, we observed significantly increased ex-
pression of DNMT1 and DNMT3A upon the initiation
of monocyte differentiation to iDCs, and significant
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significant upregulation of DNMT3B during the maturation
of iDCs to mDCs. DNMT1 is responsible for the main-
tenance of DNA methylation through mitotic divisions,
while DNMT3A/3B are de novo methyltransferases
that actively methylate DNA during multiple cellular
processes [73-75]. It has been shown that knocking
down DNMT1 and DNMT3B or inhibition by azacytidine
results in global demethylation [76]. Controversially,
DNMTs were also proposed to function as deaminases
and base excision enzymes to reduce DNA methylation
[14,77]. Recently it has also been shown that DNMTs
are capable of directly removing the hydroxymethyl
moiety from 5-hmC and the methyl group from 5-mC
in vitro or in a redox state-dependent manner [78,79].
Therefore, it is tempting to speculate that DNMTs
have a dual role in regulating DNA methylation. They
could actively demethylate DNA or de novo methylate
DNA. Interestingly, the methylation level of a CG site
located at the 5′ UTR of DNMT3B showed a gradual
increase, suggesting that the expression of DNMT3B
might also be regulated by DNA methylation (Figure 2A).
Although inhibitors of DNMTs did not affect the active
DNA methylation process during iDC formation [18],
mDCs generated with DNMT inhibitors during iDC
differentiation and maturation exhibited differences in
surface marker expression and cytokine production
[80], suggesting a possible regulatory role of DNMTs
on some specific genes. Nevertheless, our data strongly
support further investigation on the exact roles of DNMTs
in DC differentiation and maturation, possibly on an indi-
vidual gene basis at a specific timing.
Clinical implications and future directions
Our studies suggest that DNA methylation regulates key
genes and pathways in dendritic cell differentiation and
maturation. The feasibility of large-scale ex vivo generation
of DCs from patients’ monocytes allows for therapeutic ap-
plication of ex vivo-cultured DCs to bypass the dysfunction
of endogenous DCs, restore immune surveillance, induce
cancer regression and stabilization, and delay or prevent
its recurrence. While the most common paradigm of the
therapeutic application of DCs reflects their use as cancer
‘vaccines’, additional and potentially more effective possi-
bilities include the use of patients’ autologous DCs as part
of more comprehensive therapies. This involves in vivo
or ex vivo induction of tumor-reactive T cells, which
would counteract systemic and local immunosuppres-
sion in tumor-bearing hosts. Given the reversibility of
DNA methylation by demethylating reagents and the
possibility of gene-specific DNA manipulation using
long non-coding RNA [81], our observations suggest a
novel approach to regulate this process. Ex vivo-cultured
DCs can therefore be instructed to acquire distinct andoptimal functions relevant to the induction of effective
cancer immunity (DC polarization), such as the induction
of different effector functions or different homing prop-
erties of tumor-specific T cells. Our data also support a
possible role for TET enzymes and DNMTs in DC differ-
entiation and maturation, suggesting that both could be
targeted to modify the treatment efficacy of DC vaccines.
Conclusions
Locus- and time-specific DNA demethylation occurs
during the ex vivo differentiation of human monocytes
into immature dendritic cells and their maturation by
an FDA-approved cytokine cocktail. Many of such DNA
methylation changes happen near promoters, enhancers
and transcriptional factor binding sites, and are correlated
with an increase in gene expression of nearby genes. Im-
portantly, the expression level of TET2, DNMT1, DNMT3A
and DNMT3B are upregulated in a time-dependent
manner, which happens concurrently with the DNA
methylation changes, suggesting that these enzymes
may be responsible for the precise spatial and temporal
regulation of DNA methylation levels.
Methods
Ex vivo generation and maturation of dendritic cells
This study was approved by Cincinnati Children’s Hospital
Medical Center (CCHMC) Institutional Review Board and
characterized as not human subject research (CCHMC,
IRB #2012-0136). Peripheral Blood Mononuclear Cells
(PBMCs) were isolated from the blood samples of an-
onymous healthy donors from the Hoxworth Blood center
at University of Cincinnati using Ficoll-Paque Plus density
gradient centrifugation. Monocytes were then isolated
from PBMCs by CD14+ sorting with Miltenyi beads
(Miltenyi Biotec Inc., San Diego, CA, USA) and cultured in
the presence of GM-CSF (1000U/ml) and IL-4 (500U/ml)
for 4 days to induce differentiation into mostly immature
monocyte-derived DCs (iDCs) [82-85]. These DCs were
matured by culturing for an additional two days in the
presence of a Jonuleit cocktail (IL1β, IL1α, IL6, TNFα and
PGE2) [5]. Harvested cells were sorted to obtain pure
populations of the desired cell, before being subjected to
DNA methylation analysis using microarrays and pyrose-
quencing. Cells used in the time-course experiment were
directly subjected to DNA/RNA extraction.
Flow cytometry
Immature DCs and mature DCs were stained with a
LIVE/DEAD Fixable Dead Cell Stain Kit (Life Technologies,
Grand Island, NY, USA), then fixed with 2% PFA. After
fixation, the cells and appropriate controls were pre-
pared. All samples were stained with HLA-DR-PE/Cy7
(Biolegend, San Diego, CA, USA), CD83-AF647 (Biolegend,
San Diego, CA, USA), and CD83-PE (Biolegend, San Diego,
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Biosciences, San Jose, CA, USA). Flow data were analyzed
using FlowJo v9.6.1 software.
Cell sorting
CD14+ cells presorted by CD14 MicroBead Kit (Miltenyi
Biotec Inc., San Diego, CA, USA), immature DCs, and
mature DCs were stained with CD14-FITC (Biolegend,
San Diego, CA, USA), HLA-DR-PE/Cy7 (Biolegend, San
Diego, CA, USA), CD83-AF647 (Biolegend, San Diego,
CA, USA) and Live/Dead-7-AAD (eBioscience, San Diego,
CA) and sorted on a MoFlo XDP (Beckman Coulter Inc.,
Brea, CA, USA). Cells were collected in 100% FBS and
pelleted for DNA/RNA extraction.
DNA and RNA isolation
DNA and RNA were isolated from the same samples
using AllPrep DNA/RNA Micro kit (Qiagen, Valencia,
CA, USA) according to the manufacturer’s protocols.
Illumina Infinium 450 K beadchip DNA methylation
analysis
Genomic DNA was bisulfite treated and assayed by
the Illumina Infinium HumanMethylation450 BeadChip
(Illumina, San Diego, CA, USA) at the Genomics and
Microarray lab at University of Cincinnati Medical
Center. Quality of the arrays was assessed using sample-
independent and dependent internal control probes in-
cluded on the array for staining, extension, hybridization,
specificity and bisulfite conversion. One immature DC
sample exhibited low intensity for all controls, suggesting
a problematic quality of this array. Therefore, this sample
was excluded from subsequent analyses. The remaining
11 samples all had >98% CG sites detected at P = 0.01
level, and >80% bisulfite conversion rate. The signal inten-
sities were background-adjusted, normalized, and used to
calculate beta values using the methylation module. The
following CG sites were excluded from analysis: 1) CG
sites that were not detected in all samples at P = 0.01 level;
2) CG sites on X and Y chromosomes; and 3) CG sites
assayed by less than five beads in one or more samples.
These procedures resulted in 11 samples and 343,023 CG
sites for analyses.
For each of the CG sites, the beta values were compared
between monocytes and immature DC, and between im-
mature DC and mature DC using paired t tests. Given the
small sample size of the methylation array and the import-
ance of the actual methylation level, we used both P values
and absolute differences in beta values to determine
DMPs. A DMP was defined if P value ≤0.05 and absolute
differences in beta values ≥0.1. All microarray data
have been deposited to NCBI Gene Expression Omnibus
(GSE59796).To better understand the biological meaning behind
the methylome changes, the list of DMPs was imported
into Ingenuity Pathway Analysis (Ingenuity Systems,
Redwood City, CA) for pathway mapping, gene net-
work detection, and upstream regulator identification.
A cutoff of 0.05 was used for statistical significance in
IPA analysis.Bisulfite pyrosequencing
A total of 200 ng of genomic DNA from each sample was
treated with bisulfite using an EZ DNA methylation-Gold
Kit (ZYMO research, Irvine, CA, USA) according to
the manufacturer’s specifications. The bisulfite-treated
genomic DNA was amplified by PCR using unbiased
nested primers and DNA methylation was measured by
quantitative pyrosequencing using a PyroMark Q96
MD (Qiagen, Valencia, CA, USA). The DNA methylation
percentage at each CG site was determined using the
Pyromark CpG methylation software (Qiagen, Valencia,
CA, USA). SssI-treated human genomic DNA was used as
100% methylation control and human genomic DNA
amplified by GenomePlex Complete Whole Genome
Amplification (WGA) Kit (Sigma, St. Louis, MO, USA)
was used as the nonmethylated DNA control. Pri-
mer sequences used for the bisulfite pyrosequencing
reactions are shown in Additional file 10, as well as
the chromosomal coordinates in the University of
California at Santa Cruz February 2009 human genome
assembly for each CG site measured. The annealing
temperature used for all PCR reactions was between 50°C
and 55°C.Affymetrix microarray expression analysis
Microarray gene expression profile with Affymetrix
hgu133plus2 has been preprocessed by RMA (Robust
Multi-array Average) procedure, an algorithm tool to
convert the raw probe level data into a normalized expres-
sion matrix containing annotated genes [86]. Three groups
(immature DC (#3), mature DC (#4), and monocyte (#3))
of our major interest to be compared have biological
replicates. To obtain normalized expression measure-
ment, raw intensity values on all corresponding arrays
with CEL files were adjusted by background correction,
log2-transformation, normalization across arrays under
the rationale of quantile normalization that all distribu-
tions are the same, and summarization on single gene-
level intensity from combined intensity values in the
probe set by making use of median polishing. All pair-
wise comparisons to test two groups were carried out
through a t-test [87] procedure in the genefilter R pack-
age, and a simultaneous multi-group comparison was
performed by LIMMA [88]. All analyses were on the
basis of Bioconductor and R packages [86].
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Microarray data generated by different probes of one gene
were averaged and used as the expression at gene-level.
The gene-level expression was compared between mono-
cytes and immature DC using paired t tests, and between
immature and mature DCs using two-sample t tests.
False-discovery rate (FDR) was calculated with the q
value package. Differential expression was considered
when q values ≤ 0.05. The changes in expression levels
of differentially expressed genes were then correlated
with changes in beta values of DMPs, and Pearson’s
correlation coefficients were reported for CG sites in
the island, shore, shelf, and open sea.
Quantitative PCR
RNA was isolated from the Qiagen Allprep kit mentioned
above, according to manufacturer’s instructions. cDNA
was synthesized using the Superscript III kit (Life Tech-
nologies, Grand Island, NY, USA) using random hexam-
ers. Amplifications were performed using SYBR Green
PCR core reagents (Life Technologies, Grand Island, NY,
USA), and transcript levels were quantified using an ABI
7900 Sequence Detection Systems (Life Technologies,
Grand Island, NY, USA). Mean Ct value of triplicate
reaction was normalized against mean Ct value of
GAPDH and/or HPRT. Primer sequences are included
in Additional file 11.
Identification of enriched transcription factor binding motifs
We used a custom ‘library’ of 1,907 human transcription
factor (TF) binding motifs to identify TF motifs enriched
in a ‘positive’ set of sequences (those with DNA methyla-
tion changes), compared to a ‘negative’ set (a matched set
of sequences without DNA methylation changes). The
library consists of motifs taken from databases such as
Transfac [89], JASPAR [90], UniPROBE [91], and Factor-
Book [92], as well as motifs collected from individual stud-
ies such as Jolma et al. [93] and Weirauch et al. [94]. The
manuscript describing this motif library is currently in
review. We used a 51 base window (25 bases on either
side of DMP) to construct all sequence sets. We then esti-
mated the enrichment of each motif using the Pscan [95],
which ranks all motifs by P value, based on the average
best score of the motif in the sequences of the positive set,
compared to the negative set. About 2,000 motifs were
tested, so a cutoff of P <0.000005 was used (corresponding
to a P value of 0.01, corrected using Bonferroni’s conser-
vative method). Nearly identical results were achieved
using the HOMER algorithm [96] (data not shown). For
example, the top 13 motifs for the monocyte to iDC tran-
sition are all AP-1 related (for example, FOS, JUN), all
with HOMER P values <10−25. Likewise, the top 23
enriched motifs for the iDC to mDC transition all contain
a GGAA core (for example, BCL11A, SPI, and RELA).Additional files
Additional file 1: Prospective isolation of monocyte, immature
dendritic cells (iDCs) and mature dendritic cells (mDCs) using
fluorescence activated cell sorting (FACS). (A) Schematic showing the
protocol used to generate iDCs and mDCs ex vivo from monocytes. (B)
Cell populations were purified based on the combination of cell-surface
marker expressions defined as follows: monocyte, CD14+; iDCs, HLA-DR
CD83−; mDCs, HLA-DRhigh CD83+.
Additional file 2: Differentially methylated points (DMPs) identified
comparing monocyte to immature dendritic cell (iDC), and comparing
iDC to mature dendritic cell (mDC). (A) monocyte > iDC, with the same
direction of change in associated genes. (B) monocye < iDC, with the same
direction of change in associated genes. (C) monocyte versus iDC, with
mixed directions of change in associated genes. (D) iDC >mDC, with the
same direction of change in associated genes. (E) iDC <mDC, with the
same direction of change in associated genes.
Additional file 3: Significantly enriched transcription factor (TF)
binding sites around differentially methylated points (DMPs). (A)
monocyte versus immature dendritic cell (iDC) DMPs. (B) iDC versus
mature dendritic cell (mDC) DMPs.
Additional file 4: Ingenuity pathway analyses to identify
significantly enriched gene sets and pathways with DNA
methylation changes during DC differentiation from monocyte. (A)
monocyte > immature dendritic cell (iDC), with the same direction of
change in associated genes. (B) monocye < iDC, with the same direction
of change in associated genes. (C) monocyte versus iDC, with mixed
directions of change in associated genes.
Additional file 5: Ingenuity pathway analyses to identify significantly
enriched gene sets and pathways with DNA methylation changes
during dendritic cell (DC) maturation. (A) immature dendritic cell
(iDC) >mature dendritic cell (mDC), with the same direction of change in
associated genes. (B) iDC <mDC, with the same direction of change in
associated genes.
Additional file 6: Ingenuity pathway analyses to identify upstream
regulator of genes with DNA methylation changes. (A) monocyte versus
immature dendritic cell (iDC). (B) iDC versus mature dendritic cell (mDC).
Additional file 7: Correlation of DNA methylation changes with
gene expression alterations during dendritic cell (DC) maturation.
The changes in expression levels of differentially expressed genes were
correlated with changes in beta values of differentially methylated points
(DMPs), and Pearson’s correlation coefficients were reported for CG sites
in the island shore, shelf and open sea, as specified in the figure. When
all CG sites combined, n = 46, Pearson r = −0.26, P = 0.0863.
Additional file 8: Dynamic changes in expression levels of ten-eleven
translocation methylcytosine dioxygenase 2/3 (TET2/3) and
DNA-methyltransferases (DNMTs). Gene expression levels of DNMT1,
DNMT3A, and DNMT3B (A and C), TET2 and TET3 (B and D) of one donor
among four donors were plotted. Expression level was normalized to
GADPH in A and B, to HPRT in C and D. Three technical replicates were used
in each condition. Comparisons were made for Day 0 versus Day-1, Day-4
versus Mature Day-1, and Mature Day-1 versus Mature Day-2 using paired
t test. *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001.
Additional file 9: Global changes in 5mC and 5hmC during monocyte
differentiation into immature dendritic cells (iDCs) and iDC maturation
into mature dendritic cells (mDCs). A) 5-mC and B) 5-hmC were measured
by ELISA as described in Materials and Methods in the same time course
experiment as in Figure 5. C) 5-hmC in fluorescence-activated cell sorting
(FACS) purified monocytes, iDCs and mDCs. Paired student t test was used
to compare all the different groups. Results are shown as mean ± SD.
Additional file 10: Primers for bisulfite pyrosequencing and the
CpG sites interrogated.
Additional file 11: Primers for qPCR.
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